about
Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapyPalonosetron plus dexamethasone in highly emetogenic chemotherapy: pooled data from two Phase III trials.Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study.Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two pPalonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial.Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancerCombination goserelin and tamoxifen therapy in premenopausal advanced breast cancer: a multicentre study by the ITMO group. Italian Trials in Medical OncologyShould clinicians always administer dexamethasone beyond 24 h after chemotherapy to control delayed nausea and vomiting caused by moderately emetogenic regimens? Insight from the re-evaluation of two randomized studies2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy.Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy.Salvage treatment after r-interferon alpha-2a in advanced neuroendocrine tumors.Patterns and changes in gene expression following neo-adjuvant anti-estrogen treatment in estrogen receptor-positive breast cancer.Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients.Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours.Is a dexamethasone-sparing strategy capable of preventing acute and delayed emesis caused by combined doxorubicin and paclitaxel for breast cancer? Analysis of a phase II trial.Phorbol 12-myristate 13-acetate induces resistance of human melanoma cells to natural-killer- and lymphokine-activated-killer-mediated cytotoxicity.Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer.Prospective evaluation of estrogen receptor-beta in predicting response to neoadjuvant antiestrogen therapy in elderly breast cancer patients.Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women.Efficacy and tolerability of 4-hydroxyandrostenedione (4-OHA) as first-line treatment in postmenopausal patients with breast cancer after adjuvant therapy.Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients1Accepted as a poster presentation to the 34th Annual Meeting of the American Society of Clinical Oncology, May 1998, Los AngThe luteinising hormone–releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markersTumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitorsThe aromatase inhibitor letrozole in advanced breast cancer: Effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levelsEffect of two 4-hydroxyandrostenedione doses on serum insulin-like growth factor I levels in advanced breast cancerGoserelin in Premenopausal Advanced Breast Cancer: Clinical and Endocrine Evaluation of Responsive PatientsAcute confusional state with fatal outcome in a cancer patientCapecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancerVerapamil upregulates sensitivity of human colon and breast cancer cells to LAK-cytotoxicity in vitroPalonosetron plus 1-day dexamethasone for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy: effect of established risk factors on treatment outcome in a phase III trialSingle-institution series of early-stage Merkel cell carcinoma: long-term outcomes in 95 patients managed with surgery aloneResearch on chemotherapy-induced nausea: back to the past for an unmet need?Aprepitant versus dexamethasone for delayed emesis: what is the role of the 5-hydroxytryptamine type 3 receptor antagonist palonosetron?Every-other-day palonosetron plus aprepitant for prevention of emesis following induction chemotherapy for acute myeloid leukemia: A randomized, controlled study from the "Rete Ematologica Pugliese"Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence
P50
Q26783229-52A581C6-3D56-4AFA-97A1-0DE90E0CE898Q30672833-234786D1-B55F-4D5A-8AA7-9C410008713BQ33383287-1ECCCBE7-F926-4B29-9F10-BA84AC97500BQ34368190-B06382FC-4C00-4DA4-9304-D66D2E4C6A00Q35082647-9DDC0057-E5D7-46CA-BBD5-C99CDAB74DCDQ36079441-9DC97C2D-FD09-4C5E-903B-698E61D0F495Q36080911-66563F76-EF05-4506-980F-B203D2A2CE5FQ36510919-9E32DDFA-569F-49EC-9321-F846557DF27FQ38904462-2134B7AE-8475-4F1E-8F4C-FA11619FCCAFQ39173196-EB63DFCE-FEC8-4454-927C-D2734151D085Q39496857-2D0BD350-46B6-4791-BF75-B8AE4F9F4582Q39977561-2CF3055D-FC38-4B5C-870D-E59AA274FEA7Q43976058-BCBB9F3A-67B4-4A79-9FAD-DC81F29306DFQ44022304-2DC283F4-AB1A-4303-AE51-892B9B3D6BCCQ44347884-FB1DCB44-CB0B-4B29-9B9A-039C80415553Q44413550-B805A67B-2D7D-4438-9565-ABED90DC8FD9Q44592610-0B296954-BBD8-4D5F-8F9F-610051D41DA8Q45197440-ED2E0F7B-741D-4452-A51E-A15AF21CD21CQ45265088-8211C680-4848-4E1E-BC82-2443F70E46A5Q54243381-7B86F07A-34C4-4782-A184-6D4EC4E2D7F7Q57763490-6E5EB155-0C3F-4BCE-917D-988C0D16755BQ60168351-7B88A3DF-5F2B-4584-A67A-E456CF7D4574Q60168353-996F7C31-7EA1-4AB5-97BB-18279031E970Q60168382-BCF534BC-40F4-4D9C-A8F5-01C83E412558Q60168387-E9F213DD-99D6-4CF6-A563-CDCAD53D3F25Q60168389-572F6990-C95E-4EF3-89B4-34B1F853BECBQ60678666-D8EB9F4C-62A7-48C5-89C7-8EFF2641EF1DQ61628340-0FEBC361-1D77-4C85-B9A3-EA74030032C4Q67904835-A37D1586-7486-49E7-994E-6E6C4741FE77Q82061044-4D117770-5E86-4D5C-AB94-960FA368C18DQ84243624-85168B3F-2CD5-46EF-8698-CF56803A87FDQ86169086-B453176E-7885-4589-B0D4-F77E5D949DABQ88045993-2BB4C868-01A9-436F-B07B-A1AAFB891D4FQ91278425-A23D4AC5-ABF5-43DE-9B7B-4293A4ED49AAQ92330971-74E4B020-1903-4D49-BFAB-C86553198BB1
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Luigi Celio
@ast
Luigi Celio
@en
Luigi Celio
@es
Luigi Celio
@nl
Luigi Celio
@sl
type
label
Luigi Celio
@ast
Luigi Celio
@en
Luigi Celio
@es
Luigi Celio
@nl
Luigi Celio
@sl
prefLabel
Luigi Celio
@ast
Luigi Celio
@en
Luigi Celio
@es
Luigi Celio
@nl
Luigi Celio
@sl
P1053
D-2454-2017
P106
P1153
6603759937
P21
P31
P3829
P496
0000-0001-6849-9838